Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    "gene therapy" AND lentivirus OR "gene transfer" AND lentivirus
Show Display Options
Rank Status Study
1 Recruiting Gene Transfer for Patients With Sickle Cell Disease
Conditions: Sickle Cell Disease;   Sickle Cell Anemia
Intervention: Genetic: Gene transfer
2 Recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-related Non-Hodgkin Lymphoma;   AIDS-related Plasmablastic Lymphoma;   AIDS-related Primary Effusion Lymphoma;   HIV Infection
Interventions: Drug: busulfan;   Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells;   Other: pharmacological study;   Other: laboratory biomarker analysis
3 Active, not recruiting Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large B-cell Lymphoma;   AIDS-Related Plasmablastic Lymphoma;   AIDS-Related Primary Effusion Lymphoma;   HIV Infection;   AIDS Related Non-Hodgkin Lymphoma
Interventions: Drug: Prednisone;   Biological: Rituximab;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
4 Terminated Gene Transfer for HIV Using Autologous T Cells
Condition: HIV-1 Infection
Intervention: Genetic: pHIV7-shI-TAR-CCR5RZ treated CD4 cells
5 Recruiting Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Conditions: HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
6 Active, not recruiting Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
Condition: Lymphoma
Interventions: Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: autologous hematopoietic stem cell transplantation
7 Suspended Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
Conditions: X-linked Severe Combined Immunodeficiency;   XSCID;   SCID-X1;   Gamma C-Deficient SCID
Interventions: Other: Gene-modified CD34+ Hematopoietic stem cells;   Drug: Busulfan
8 Recruiting Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease
Condition: Granulomatous Disease, Chronic, X-linked
Intervention: Biological: Lentiviral G1XCGD Gene Therapy
9 Active, not recruiting Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)
Condition: ADA-SCID
Intervention: Genetic: EFS-ADA transduced CD34+ cells from the bone marrow
10 Enrolling by invitation Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Conditions: Pediatric Cancers;   Hematologic Malignancies;   Solid Tumors
Intervention:
11 Recruiting CART-meso Long-term Follow-up
Condition: Subjects Who Have Received Lentiviral-based CART-meso Therapy
Intervention: Biological: lentiviral-based CART meso therapy
12 Recruiting Gene Therapy for Fanconi Anemia
Condition: Fanconi Anemia
Interventions: Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells;   Procedure: Harvest Procedure;   Other: Laboratory Biomarker Analysis
13 Completed Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Hydroxyurea
14 Recruiting Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Biological: Lentivirus Alpha-gal A transduced stem cells
15 Recruiting CD19 CART Long Term Follow Up (LTFU) Study
Condition: Safety LTFU, Pts Receiving CD19 Directed CAR T-Cell Therapy
Intervention: Genetic: Previously treated CART CD 19 patients
16 Active, not recruiting Gene Therapy for Wiskott-Aldrich Syndrome
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with WAS encoding lentiviral vector.
17 Recruiting Gene Therapy for WAS Follow-up
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34+ cells transduced with WASP lentiviral vector
18 Recruiting Gene Therapy for WAS
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
19 Recruiting Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
20 Active, not recruiting A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease
Conditions: Beta-Thalassemia Major;   Sickle Cell Disease
Intervention: Genetic: LentiGlobin BB305 Drug Product

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.